PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Bianca M. Conti-Fine

Examiner: Patrick J. Nolan ECEIVED

Serial No.:

08/991,143

Group Art Unit: 1644

AUG 0 3 2001

Filed:

December 16, 1997

Docket: 600.423USL

TECH CENTER 1600/2900

Title:

METHODS TO TREAT UNDESIRABLE IMMUNE RESPONSES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant further request that a copy of the 1449 form, initialled by the Examiner to indicate that all listed citations have been considered, be returned with the next official communication.

Applicant have included the fee of \$180.00 under 37 C.F.R. §§ 1.97(c) and 1.17(p). Please charge any additional fees or credit any overpayment to Account No. 19-0743.

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

BIANCA M. CONTI-FINE

By his Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6959

Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 250 day of July, 2001.

Alisia G Dunbar

Signature

08/01/2001 ADSHAN1 00000037 08991143 01 FC:126 180.